The first 60 days: Malignant peripheral nerve sheath tumour (MPNST)
Malignant peripheral nerve sheath tumour is a sarcoma that grows from the covering of a nerve, most often in people with neurofibromatosis type 1 when a benign plexiform neurofibroma turns malignant. Surgery with radiotherapy is the only cure; chemotherapy with doxorubicin and ifosfamide shrinks some tumours, and drugs targeting the tumour's lost NF1 and PRC2 brakes are in trials. Below, week by week, is what OnCo's record of Malignant peripheral nerve sheath tumour (MPNST) says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Neurofibromatosis type 1 surveillance.
- RadiologistNamed in the standard of care for: Neurofibromatosis type 1 surveillance.
- SurgeonNamed in the standard of care for: Localised.
- Medical oncologistNamed in the standard of care for: Localised, Advanced, Neurofibromatosis type 1 surveillance.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Localised.
- Transplant and cell therapy teamNamed in the standard of care for: Advanced.
- Palliative and supportive care teamNamed in the standard of care for: Localised, Advanced.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Wide resection with preoperative or postoperative radiotherapy; nerve sacrifice and reconstruction as needed; consider neoadjuvant or adjuvant anthracycline-ifosfamide for large high-grade tumours.
- 2.Advanced
Doxorubicin plus ifosfamide (EORTC 62012), then ifosfamide-etoposide or trials; response rates lower in NF1-associated tumours.
Whole-body MRI and FDG-PET for growing or painful plexiform neurofibromas; biopsy of atypical lesions; MEK inhibitors for symptomatic plexiform neurofibromas.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Loss of H3K27 trimethylation on immunohistochemistry, NF1, CDKN2A, SUZ12 or EED alterations, TP53 loss, FDG-PET uptake in neurofibromas, Germline NF1 status), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include NF1-associated MPNST, Sporadic MPNST, Radiation-associated MPNST.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Localised
- For my situation (localised), which of the standard options do you recommend and why?Guideline options include: Wide resection with preoperative or postoperative radiotherapy; nerve sacrifice and reconstruction as needed; consider neoadjuvant or adjuvant anthracycline-ifosfamide for large high-grade tumours.
- Am I a candidate for Doxorubicin, Ifosfamide, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Advanced
- For my situation (advanced), which of the standard options do you recommend and why?Guideline options include: Doxorubicin plus ifosfamide (EORTC 62012), then ifosfamide-etoposide or trials; response rates lower in NF1-associated tumours.
- Am I a candidate for Doxorubicin, Ifosfamide, Etoposide, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of EORTC 62012 apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Neurofibromatosis type 1 surveillance
- For my situation (neurofibromatosis type 1 surveillance), which of the standard options do you recommend and why?Guideline options include: Whole-body MRI and FDG-PET for growing or painful plexiform neurofibromas; biopsy of atypical lesions; MEK inhibitors for symptomatic plexiform neurofibromas.
- Am I a candidate for Selumetinib, Mirdametinib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Selumetinib, Mirdametinib, MEK1/2, RAS / RAF / MEK / ERK (MAPK)?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Metastasis is common even after complete local treatment”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Chemotherapy works less well in the NF1-associated tumours that make up half of cases”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Malignant peripheral nerve sheath tumour (MPNST): the full pageMalignant peripheral nerve sheath tumour is a sarcoma that grows from the covering of a nerve, most often in people with neurofibromatosis type 1 when a benign plexiform neurofibroma turns malignant. Surgery with radiotherapy is the only cure; chemotherapy with doxorubicin and ifosfamide shrinks some tumours, and drugs targeting the tumour's lost NF1 and PRC2 brakes are in trials.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.